Lunai Bioworks

Hello! 👋 We’re Lunai Bioworks. Decoding life. Discovering cures. Our AI-powered phenomics platform captures disease in motion, decoding biology at scale to bring clarity to complexity.

Lunai Bioworks will be at the BIO International Convention in San Diego on June 22-25, and we’re looking to connect with potential partners in biotech and drug discovery. #BIO2026 #Biotech #Partnerships

We at Lunai Bioworks support this week’s open letter on nucleic acid synthesis screening and record-keeping. It shows broad alignment around practical biosecurity safeguards, including the CEOs of @OpenAI, @AnthropicAI, and @MicrosoftAI. #Biosecurity #Biodefense #AIinBiology

Lunai Bioworks has completed and expanded our previously announced $20M CNS-focused transaction through the NeuroBridge IP acquisition, adding complementary brain-delivery capabilities to our CNS platform. #CNS #DrugDelivery #Neuroscience

Lunai Bioworks (NASDAQ: LNAI) has announced a $20M transaction to acquire blood-brain barrier (BBB) delivery technology and CNS Alzheimer’s drug assets from the Clemann Group. BBB delivery is a major bottleneck in CNS drug development. #Alzheimers #CNS #BloodBrainBarrier